Table 2.

Efficacy of Approved First-Line Antiviral Therapies in Adults with Treatment-Naïve Chronic Hepatitis B and Immune-Active Disease (Not Head-to-Head Comparisons)

HBeAg Positive	Peg-IFN1	Entecavir2	Tenofovir Disoproxil Fumarate2	Tenofovir Alafenamide3
% HBV DNA suppression (cutoff to define HBV DNA suppression)4	30–42 (<2000–40,000 IU/mL) 8–14 (<80 IU/mL)	61 (<50–60 IU/mL)	76 (<60 IU/mL)	73 (<29 IU/mL)
% HBeAg loss	32–36	22–25	--	22
% HBeAg seroconversion	29–36	21–22	21	18
% Normalization ALT	34–52	68–81	68	--
% HBsAg loss	2–7 11 (at 3 years posttreatment)	2–3 4–5 (2 years)	3 8 (3 years)	1 (2 years)
HBeAg Negative	Peg-IFN	Entecavir	Tenofovir Disoproxil Fumarate2	Tenofovir Alafenamide3
% HBV DNA suppression (cutoff to define HBV DNA suppression)5	43 (<4000 IU/mL) 19 (<80 IU/mL)	90–91 (<50–60 IU/mL)	93 (<60 U/mL)	90 (<29 IU/mL)
% Normalization ALT6	59	78–88	76	81
% HBsAg loss	4 6 (at 3 years posttreatment)	0–1	0	<1

References: (6–16)

¹Assessed 6 months after completion of 12 months of therapy

²Assessed after 3 years of continuous therapy

³Assessed after 2 years of continuous therapy

⁴HBV DNA <2000–40,000 IU/mL for peginterferon; <60 IU/mL for entecavir and tenofovir disoproxil fumarate; <29 IU/mL for tenofovir alafenamide

⁵HBV DNA <20,000 IU/mL for peginterferon; <60 IU/mL for entecavir and tenofovir disoproxil fumarate; <29 IU/mL for tenofovir alafenamide

⁶ALT normalization defined by laboratory normal rather than ≤35 and ≤25 U/L for males and females